The Effect of General Anesthesia with Remimazolam and Propofol on Rhythmic State and Cognitive Function
Launched by THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY · Jan 9, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how two common anesthesia medications, remimazolam and propofol, affect patients' brain function and daily rhythms after surgery. The researchers want to see if using remimazolam can help patients recover better and avoid problems with thinking clearly after their surgery compared to those receiving propofol. The trial will involve patients aged 18 to 65 who are scheduled for a specific type of surgery called laparoscopic cholecystectomy, which typically takes about 1.5 to 2.5 hours.
To participate, individuals must meet certain criteria, including having a stable weight and a good mental status before surgery. They should not have serious health issues or a history of substance abuse. Participants will receive either remimazolam or propofol during their procedure, and the study aims to monitor their recovery and cognitive function afterward. Overall, this trial is an important step toward understanding how different anesthetics can affect patient outcomes after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-65 years old, ASAI-III class, BMI18.5-25kg/m2 Inpatients undergoing laparoscopic cholecystectomy The estimated time of operation is 1.5\~2.5 hours Preoperative brief mental status examination (MMSE) score ≥24 Voluntary participation and signed informed consent
- Exclusion Criteria:
- • Pregnant or lactating women Patients who are allergic to remimazolam or contraindicated Patients who are dependent on or tolerant to opioids or have long-term alcoholism Serious cardiovascular system, respiratory system, liver and kidney diseases History of obstructive sleep apnea mental disorders or neurological diseases Patients who participated in clinical trials of other drugs within the last 3 months The attending physician or researcher considers that there are other circumstances that are not suitable for participation in this study Refuse to participate in the study
About The Second Affiliated Hospital Of Chongqing Medical University
The Second Affiliated Hospital of Chongqing Medical University is a leading healthcare institution dedicated to advancing medical research and patient care through innovative clinical trials. As a prominent academic hospital in China, it combines cutting-edge medical technology with a strong emphasis on education and training for healthcare professionals. The hospital is committed to conducting high-quality, ethically sound clinical research that contributes to the development of new therapies and enhances healthcare outcomes. With a multidisciplinary team of experts, the Second Affiliated Hospital fosters collaboration and strives to address critical health challenges through rigorous scientific investigation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chongqing, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported